Cellectis (NASDAQ:CLLS) had its target price raised by stock analysts at Nomura to $73.00 in a report issued on Wednesday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Nomura’s target price suggests a potential upside of 108.04% from the stock’s previous close.
Other equities research analysts have also issued research reports about the company. BidaskClub raised Cellectis from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 17th. Zacks Investment Research lowered Cellectis from a “buy” rating to a “hold” rating in a report on Thursday, November 16th. ValuEngine raised Cellectis from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of Cellectis in a report on Thursday, December 28th. One analyst has rated the stock with a sell rating, two have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $42.67.
Shares of Cellectis (NASDAQ:CLLS) traded up $3.44 on Wednesday, reaching $35.09. The company’s stock had a trading volume of 446,664 shares, compared to its average volume of 178,625. Cellectis has a 12 month low of $21.25 and a 12 month high of $35.94. The stock has a market cap of $1,150.00 and a price-to-earnings ratio of -12.46.
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.